A pro­tein en­gi­neer­ing plat­form spawns a new IL-2 play­er out of Basel, with hu­man tri­als loom­ing next sum­mer

Ver­sant Ven­tures is de­but­ing an­oth­er biotech up­start this morn­ing that its part­ners be­lieve has big po­ten­tial for de­vel­op­ing pipelines in prod­ucts cre­at­ed by its own unique plat­form tech. And they have their sights set first on one of the hottest tar­gets in im­muno-on­col­o­gy.

The com­pa­ny is Bright Peak Ther­a­peu­tics, launched out of Ver­sant’s Ridge­line Ther­a­peu­tics Dis­cov­ery En­gine in Basel, which is grow­ing clin­i­cal de­vel­op­ment roots in San Diego. And they have $35 mil­lion of Ver­sant A round cash to fund their dri­ve to the clin­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.